Ib~IIb期非小细胞肺癌术后生活质量观察

Observation of Quality of Life for Ib~IIb Stage Non-Small Cell Lung Cancer after Complete Resection

摘要: 目的：通过随机对照的研究方法，用EORTC QLQ生活质量测定量表、LCSS肺癌症状量表、肺癌患者生存质量测定量表(FACT-L)、生活质量QOL评分量表、中医证候积分，研究45例Ib~IIb期非小细胞肺癌术后化疗患者生活质量的变化。方法：将符合入组条件的45例Ib~IIb期非小细胞肺癌术后患者，随机分成治疗组(金复康口服液联合化疗) 23例、对照组(单纯化疗) 22例。两组均予术后辅助含铂双药化疗2周期，治疗组在化疗的基础上，联合口服金复康口服液，完成2周期治疗后评价两组患者治疗前后生活质量及中医证候情况。结果：1) 治疗后EORTC QLQ生活质量测定量表中治疗组躯体功能、疲乏、食欲减退、睡眠障碍改善优于对照组(P < 0.05)，总体健康状况治疗组优于对照组(P < 0.01)，子量表中疲乏、气促、咳嗽症状改善疗效优于对照组(P < 0.01)；2) LCSS肺癌症状量表评分、生活质量QOL治疗组改善优于对照组(P < 0.05)；3) FACT-L量表评分治疗组改善优于对照组(P < 0.05)；4) 中医症候疗效治疗组好于对照组(P < 0.05)。结论：金复康口服液能改善术后Ib~IIb期非小细胞肺癌化疗患者的疲乏、气促、咳嗽、睡眠障碍症状，减轻化疗造成的食欲下降，改善总体健康状况，提高患者生活质量，减轻患者中医症候，具有良好的安全性。

Abstract: Objective: To evaluate the curative effect in the quality of life of 45 patients with chemotherapy af-ter surgery Ib~IIb stage non-small cell lung cancer, by using the randomized and controlled method. The main outcome measures are the EORTC QLQ Quality of Life Measurement Scale, Lung Cancer Symptom Scale (LCSS), Functional Assessment of Cancer Therapy (FACT-L), Quality of Life QOL Score Scale and Traditional Chinese Medicine Syndrome Score. Methods: 45 cases of non-small cell lung cancer patients in the Ib~IIb stage after complete resection were randomizedly divided into two groups according to the order of the patients. One group was the treatment group (Jinfukang Oral liquid combined chemotherapy), which included 23 patients. The other group was the control group (chemotherapy), which included 22 patients. Both two groups received 2 cycles of platinum-based chemotherapy. The treatment group was added to Jinfukang oral liquid. To evaluate the curative effect of two groups in the term of quality of life, TCM symptoms before and after completing 2 cycles of treatment. Results: 1) The improvement of physical function, fatigue, loss of appetite and sleep disorder in the treatment group on the EORTC QLQ quality of life measurement scale after treat-ment was better than that of the control group (P < 0.05), the treatment group of general health was better than that of the control group (P < 0.01), and the improvement of fatigue, shortness of breath and cough symptoms on the subscale was better than that of the control group (P < 0.01). 2) The LCSS lung cancer symptom scale score and quality of life QOL treatment group improved better than the control group (P < 0.05); 3) The improvement of the FACT-L scale scoring treatment group was better than that of the control group (P < 0.05); 4) The treatment group of TCM symptoms was bet-ter than that of the control group (P < 0.05). Conclusion: Jinfukang oral liquid can improve the symptoms of fatigue, shortness of breath, cough and sleep disorder in postoperative stage Ib~IIb non-small cell lung cancer chemotherapy patients, reduce the loss of appetite caused by chemo-therapy, improve the overall health status, improve the quality of life of patients, and reduce TCM symptoms , and has a good safety profile.